The "Microneedles for Drug Delivery Patent Landscape" report has been added to ResearchAndMarkets.com's offering.
The global drug delivery market has been observed to be as large as USD 440.5 billion in 2018.
Hypodermic needles are known to be very efficient and they have been used immensely in the delivery of biological macromolecules, insulin, vaccines, etc. However, their invasive nature, stability issues, and non-compliance have always been the issues of concern and led to the requirement of highly skilled medical practitioners for administration.
In this context, microneedles have shown immense potential, since they can easily, painlessly and safely deliver drugs without special storage infrastructure. Hence, they can be self-administered by anybody, thereby eliminating the need for a clinic visit and the assistance of skilled medical practitioners. This serves as an important advantage, especially in the emerging markets. Moreover, microneedles do not create sharp waste, thereby eliminating the problem of discarding needles and hazardous risks. Patients suffering from needle phobia can easily use microneedles. Indeed, according to a study published in Behavioral Neurology, 2014, around 3-4% of the world population faces needle phobia.
Microneedles for drug delivery are attracting interest from big companies and start-ups alike and show immense potential that could transform the global transdermal market. Furthermore, in the actual race to find a COVID-19 vaccine, numerous companies (e.g. Kindeva (3M), Debiotech, Verndari, NanoPass, Bioserentach, Sorrento Therapeutics, Merck, etc.) have developed or shared their microneedle delivery system and promising results have already been released. Other fields, like cosmetic, ophthalmic and diabetes showed important technological progress in the past few years that could disrupt the existing market and replace the current standard drug delivery system.
In this evolving context, it is crucial to understand the intellectual property position and strategy of these different players. Such knowledge can help detect business risks and opportunities, anticipate emerging technologies, and enable strategic decisions to strengthen one's market position.
Report's Key Features
PDF with > 140 slides
Excel file > 2,450 patent families
IP trends, including time-evolution of published patents, and countries of patent filings
Patents' legal status
Ranking of main patent assignees
Key players' IP position and relative strength of their patent portfolios
Summary of the IP related to applications: Cancer therapy, Cosmetic, Diabetes, Ophthalmic, Pain management and Vaccine.
Summary of the IP related to technologies: Applicators, housing, Coated, Hollow, Porous, Soluble, Hydrogel and Solid microneedles.
Analysis of patent oppositions (Europe) and review of key patents.
Excel database containing all patents analyzed in the report, including applications and technologies segmentations
Key Topics Covered:
Definition of microneedle
Scope of the report
Key features of the report
Objectives of the report
Patent search, patent selection and patent analysis
Terminologies for patent analysis
Strength and blocking potential of patent portfolio
3. MAIN PATENT ASSIGNEES
4. EXECUTIVE SUMMARY
5. PATENT LANDSCAPE OVERVIEW
Time evolution of patent publications
Countries of patent filings
Time evolution by country
Main Patent Assignees
Main IP Players
Patent legal status
Mapping of main current IP holders
Patenting activity of IP leading companies
Time evolution of main patent assignees
Main IP collaborations
6. IP POSITION OF MAIN PATENT APPLICANTS
Beyond Quantity: Quantity Quality
IP leadership of patent assignees
Prior art blocking potential
7. KEY PATENTS
Patent forward citation analysis
Key patent families
Main oppositions on EP patents
8. PATENT SEGMENTATION
Main assignees by application
Main assignees by type of microneedles
Main assignees by IP position and technology
Matrix applications vs technologies
9. IP PROFILE OF KEY PLAYERS
11. PUBLISHER PRESENTATION
Johnson & Johnson
LG Household & Health Care
LTS Lohmann Therapy Systems
Procter & Gamble
For more information about this report visit https://www.researchandmarkets.com/r/uk0bvx
View source version on businesswire.com: https://www.businesswire.com/news/home/20200810005433/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900